~~<i id='8CA367D31E'><strike id='8CA367D31E'><tt id='8CA367D31E'><pre id='8CA367D31E'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

focus

author：explore 2025-09-07 21:54:03 - browse：652

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Departing Stanford president retracts two papers

hotspot

focus

Wikipedia

focus

entertainment

hotspot

AdobeTheDepartmentofHealthandHumanServicesannouncedThursdaythatitisfillingeightvacancies,includingth

WSS

As pharma fights Medicare drug negotiation, hospitals, docs silent

Resistance to opioid

Feds fine Medicare Advantage plans for overcharging members

Bernie Sanders gets little from pharma CEOs on drug prices

Tome Biosciences co

AMAs digital advisors table RPM coding reform proposal, again

hotspot

focus

hotspot

How one medical school became remarkably diverse

Ebola vaccine can save some who are already sick, per new study

Hepatitis C has a cure — but many Americans still lack access to it

Congress might make insulin pumps more accessible to the blind

Peter Hotez and the public health issue of online harassment

Websites selling Wegovy, Zepbound ingredients targeted by FDA

After affirmative action ruling, medical educators look to 'holistic review'

Abbott's new heart device gets FDA advisory panel nod

State Dept. review finds Biden bears some blame for Afghanistan failures

Websites selling Wegovy, Zepbound ingredients targeted by FDA

focus

How a symptom of dementia informs our understanding of creativity

AMAs digital advisors table RPM coding reform proposal, again

Drug firms test therapies to halt Alzheimer’s before symptoms arise

NYU Langone launches private ChatGPT for its health care data

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Wikipedia

focus

entertainment

hotspot